RPT 1G
Alternative Names: RPT-1GLatest Information Update: 07 Mar 2026
At a glance
- Originator Remedy Plan Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
- Preclinical Solid tumours
Most Recent Events
- 06 Dec 2025 Pharmacodynamics data from the preclinical trial in Non-Hodgkin's lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
- 06 Dec 2025 Adverse events, pharmacodynamics and pharmacokinetics data from the phase I trial in Haematological malignancies presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
- 04 Dec 2025 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) (PO) prior to December 2025 (NCT07107126)